Focal hypertrichosis during topical tacrolimus therapy for childhood vitiligo [5]

Pediatric Dermatology

Volumn 22, Issue 1, 2005, Pages 86-87

  Prats Caelles, Iolanda ^a   Herranz Pinto, Pedro ^a   López De Ayala Casado, Eduardo ^a   De Lucas Laguna, Raúl ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

MACROLIDE; TACROLIMUS;

CASE REPORT; CLINICAL EXAMINATION; CLINICAL FEATURE; DRUG ACTIVITY; FEMALE; HAIR GROWTH; HUMAN; HYPERTRICHOSIS; HYPOPIGMENTATION; KNEE; LETTER; PHYSICAL EXAMINATION; PRIORITY JOURNAL; SCHOOL CHILD; TREATMENT OUTCOME; VITILIGO;

ADMINISTRATION, CUTANEOUS; CHILD; FEMALE; HUMANS; HYPERTRICHOSIS; IMMUNOSUPPRESSIVE AGENTS; TACROLIMUS; VITILIGO;

EID: 12944281625     PISSN: 07368046     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1525-1470.2005.22123.x     Document Type: Letter

References (5)

1. Lepe V, Moncada B, Castanedo-Cazares JP, et al. A double-blind randomized trial of 0.1% tacrolimus vs 0.05% clobetasol for the treatment of childhood vitiligo. Arch Dermatol 2003;139:581-585.
2. Yamamoto S, Jiang H, Kato R. Stimulation of hair growth by topical application of FK506: a potent immunosuppresive agent. J Invest Dermatol 1994;102(2):160-164.
3. Feldman KA, Kunte C, Wollenberg A, et al. Is topical tacrolimus effective in alopecia areata universalis? Br J Dermatol 2002;147:1031-1032.
4. Park SW, Kim JW, Wang HY. Topical tacrolimus (FK506): a treatment failure in four cases of alopecia universalis. Acta Derm Venereol 2002;82:387-388.
5. Jiang H, Yamamoto S, Kato R. Induction of anagen in telogen mouse skin by topical application of FK506, a potent immunosuppressant. J Invest Dermatol 1995;104:523-525.